Literature DB >> 26572085

Prostate cancer: Galeterone ARMORs up against CRPC.

Annette Fenner.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26572085     DOI： 10.1038/nrurol.2015.279

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.

Authors:  Bruce Montgomery; Mario A Eisenberger; Matthew B Rettig; Franklin Chu; Roberto Pili; Joseph J Stephenson; Nicholas J Vogelzang; Alan J Koletsky; Luke T Nordquist; William J Edenfield; Khalid Mamlouk; Karen J Ferrante; Mary-Ellen Taplin
Journal:  Clin Cancer Res       Date:  2015-11-02       Impact factor: 12.531
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.